In the past week, RLAY stock has gone up by 5.57%, with a monthly gain of 36.60% and a quarterly surge of 59.33%. The volatility ratio for the week is 7.74%, and the volatility levels for the last 30 days are 7.32% for Relay Therapeutics Inc The simple moving average for the past 20 days is 29.11% for RLAY’s stock, with a 14.60% simple moving average for the past 200 days.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
RLAY has 36-month beta value of 1.68. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RLAY is 119.27M, and currently, short sellers hold a 6.75% ratio of that float. The average trading volume of RLAY on July 24, 2024 was 1.36M shares.
RLAY) stock’s latest price update
Relay Therapeutics Inc (NASDAQ: RLAY)’s stock price has increased by 7.73 compared to its previous closing price of 8.80. However, the company has seen a 5.57% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-06 that 3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Barclays repeating the rating for RLAY by listing it as a “Overweight.” The predicted price for RLAY in the upcoming period, according to Barclays is $15 based on the research report published on May 10, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $12.50. The rating they have provided for RLAY stocks is “Hold” according to the report published on April 20th, 2023.
Raymond James gave a rating of “Strong Buy” to RLAY, setting the target price at $29 in the report published on April 19th of the previous year.
RLAY Trading at 33.28% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.94% of loss for the given period.
Volatility was left at 7.32%, however, over the last 30 days, the volatility rate increased by 7.74%, as shares surge +37.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.24% upper at present.
During the last 5 trading sessions, RLAY rose by +5.57%, which changed the moving average for the period of 200-days by +10.36% in comparison to the 20-day moving average, which settled at $7.47. In addition, Relay Therapeutics Inc saw -13.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Catinazzo Thomas, who sale 9,373 shares at the price of $6.24 back on Jun 27 ’24. After this action, Catinazzo Thomas now owns 330,430 shares of Relay Therapeutics Inc, valued at $58,493 using the latest closing price.
Bergstrom Donald A, the President, R&D of Relay Therapeutics Inc, sale 648 shares at $6.26 during a trade that took place back on Jun 27 ’24, which means that Bergstrom Donald A is holding 526,779 shares at $4,056 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -10.3 for the present operating margin
- 0.85 for the gross margin
The net margin for Relay Therapeutics Inc stands at -9.32. The total capital return value is set at -0.45. Equity return is now at value -40.40, with -35.03 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.42. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -52.47.
Currently, EBITDA for the company is -380.57 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 32.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.73.
Conclusion
To put it simply, Relay Therapeutics Inc (RLAY) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
